Rafal Kaminski
Chief Scientific Officer Angelini Pharma Inc
Dr Rafal Kaminski has broad experience in the discovery and development of innovative drugs. After obtaining medical degree and doctorate in pharmacology at the Medical University of Lublin (Poland), he completed his post-doctoral training in the Netherlands (Radboud University) and USA (National Institutes of Health), as well as obtained the Diploma in Pharmaceutical Medicine (ULB, Belgium). Currently, Dr Kaminski is Chief Scientific Officer and Global Head of R&D at Angelini Pharma (Italy). Before that he held various leadership roles in R&D organizations at UCB Pharma (Belgium), Roche (Switzerland) and Molecure Therapeutics (Poland). He co-authored more than 100 peer-reviewed publications and is also co-inventor in several patents.
Seminars
With BBB-penetrating technologies at the forefront of Korean innovation, the next frontier lies in moving beyond antibody shuttles to explore receptor‑mediated transcytosis for delivering therapeutic oligonucleotides to the brain. In this interactive workshop, explore the possibilities of platforms such as ABL Bio’s Grabody-B being utilized to shuttle ASOs and siRNAs across the BBB, and ponder questions such as:
- What do we understand about the behaviour of oligonucleotides when conjugated to antibodies and how can we optimize the conjugation for effective delivery?
- How can we overcome the challenge of siRNA negative charge limiting intracellular delivery in the CNS?
- How can we maximize endosomal escape of IV-administered oligonucleotides in the CNS?
- What are the advantages of delivering oligonucleotides via RMT vs intrathecal administration?
- Exploring the latest RNA editing approaches to target APOE, such as Rznomics’ trans-splicing-induced replacement of APOE4
- Discussing the potential of RNAi platforms to transverse the BBB and silence disease-causing genes in the brain
- Evaluating opportunities for ASOs, such as Sovargen’s SVG105, to achieve greater efficacy than conventional gene and small molecule therapies in epilepsies
- Evaluating novel exosome-based and lipid carrier platforms for CNS-targeted RNA therapeutics
- Exploring how to leverage novel modalities to target epilepsy, neurodevelopmental disorders, depression, neuromuscular diseases and more
- Referencing Angelini’s ASO-centered partnership with Sovargen
- Discussing novel formulation approaches including LNPs for enhanced CNS targeting
